Form 8-K - Current report:
SEC Accession No. 0001193125-23-022182
Filing Date
2023-02-02
Accepted
2023-02-02 08:30:11
Documents
56
Period of Report
2023-02-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d425744d8k.htm   iXBRL 8-K 31160
2 EX-99.1 d425744dex991.htm EX-99.1 47126
3 EX-99.2 d425744dex992.htm EX-99.2 42302
7 GRAPHIC g425744ex99_1s10g1.jpg GRAPHIC 271470
8 GRAPHIC g425744ex99_1s11g1.jpg GRAPHIC 246089
9 GRAPHIC g425744ex99_1s12g1.jpg GRAPHIC 344228
10 GRAPHIC g425744ex99_1s13g1.jpg GRAPHIC 171090
11 GRAPHIC g425744ex99_1s14g1.jpg GRAPHIC 264303
12 GRAPHIC g425744ex99_1s15g1.jpg GRAPHIC 268797
13 GRAPHIC g425744ex99_1s16g1.jpg GRAPHIC 228837
14 GRAPHIC g425744ex99_1s17g1.jpg GRAPHIC 137447
15 GRAPHIC g425744ex99_1s18g1.jpg GRAPHIC 153602
16 GRAPHIC g425744ex99_1s19g1.jpg GRAPHIC 280838
17 GRAPHIC g425744ex99_1s1g1.jpg GRAPHIC 368406
18 GRAPHIC g425744ex99_1s20g1.jpg GRAPHIC 372639
19 GRAPHIC g425744ex99_1s21g1.jpg GRAPHIC 332373
20 GRAPHIC g425744ex99_1s22g1.jpg GRAPHIC 260447
21 GRAPHIC g425744ex99_1s23g1.jpg GRAPHIC 202964
22 GRAPHIC g425744ex99_1s24g1.jpg GRAPHIC 207502
23 GRAPHIC g425744ex99_1s25g1.jpg GRAPHIC 229965
24 GRAPHIC g425744ex99_1s26g1.jpg GRAPHIC 135578
25 GRAPHIC g425744ex99_1s27g1.jpg GRAPHIC 352637
26 GRAPHIC g425744ex99_1s28g1.jpg GRAPHIC 318089
27 GRAPHIC g425744ex99_1s29g1.jpg GRAPHIC 253762
28 GRAPHIC g425744ex99_1s2g1.jpg GRAPHIC 545355
29 GRAPHIC g425744ex99_1s30g1.jpg GRAPHIC 203133
30 GRAPHIC g425744ex99_1s31g1.jpg GRAPHIC 263737
31 GRAPHIC g425744ex99_1s32g1.jpg GRAPHIC 278924
32 GRAPHIC g425744ex99_1s33g1.jpg GRAPHIC 265097
33 GRAPHIC g425744ex99_1s34g1.jpg GRAPHIC 322883
34 GRAPHIC g425744ex99_1s35g1.jpg GRAPHIC 254213
35 GRAPHIC g425744ex99_1s36g1.jpg GRAPHIC 234785
36 GRAPHIC g425744ex99_1s37g1.jpg GRAPHIC 200454
37 GRAPHIC g425744ex99_1s38g1.jpg GRAPHIC 204920
38 GRAPHIC g425744ex99_1s39g1.jpg GRAPHIC 314049
39 GRAPHIC g425744ex99_1s3g1.jpg GRAPHIC 198448
40 GRAPHIC g425744ex99_1s40g1.jpg GRAPHIC 133068
41 GRAPHIC g425744ex99_1s41g1.jpg GRAPHIC 352637
42 GRAPHIC g425744ex99_1s4g1.jpg GRAPHIC 216653
43 GRAPHIC g425744ex99_1s5g1.jpg GRAPHIC 323852
44 GRAPHIC g425744ex99_1s6g1.jpg GRAPHIC 214003
45 GRAPHIC g425744ex99_1s7g1.jpg GRAPHIC 216290
46 GRAPHIC g425744ex99_1s8g1.jpg GRAPHIC 307507
47 GRAPHIC g425744ex99_1s9g1.jpg GRAPHIC 277355
48 GRAPHIC g425744g0202071059974.jpg GRAPHIC 2791
  Complete submission text file 0001193125-23-022182.txt   15057033

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA clsd-20230202.xsd EX-101.SCH 2852
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE clsd-20230202_lab.xml EX-101.LAB 17993
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clsd-20230202_pre.xml EX-101.PRE 11262
50 EXTRACTED XBRL INSTANCE DOCUMENT d425744d8k_htm.xml XML 3361
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA GA 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

EIN.: 452437375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37783 | Film No.: 23578883
SIC: 2834 Pharmaceutical Preparations